Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Open access
van den Ende, Tom, de Clercq, Nicolien C., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Geijsen, E.D., Verhoeven, R.H.A., Meijer, Sybren L., Schokker, Sandor, Dings, M.P.G., Bergman, Jacques J.G.H.M., Haj Mohammad, Nadia, Ruurda, Jelle P., van Hillegersberg, Richard, Mook, Stella, Nieuwdorp, Max, de Gruijl, Tanja D., Soeratram, Tanya T.D., Ylstra, Bauke, van Grieken, Nicole C.T., Bijlsma, Maarten F., Hulshof, Maarten C.C.M., van Laarhoven, H.W.M. · 2021 · Clinical Cancer Research

Abstract

Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-1 (PD-L1) inhibition for rEAC. Patients and Methods: Patients with rEAC received nCRT according to the CROSS regimen combined with five cycles of atezolizumab (1,200 mg). The primary endpoint was the feasibility of administering five cycles of atezolizumab in ≥75% patients. A propensity score–matched nCRT cohort was used to compare pathologic response, overall survival, and progression-free survival. Exploratory biomarker analysis was performed on repeated tumor biopsies. Results: We enrolled 40 patients of whom 85% received all cycles of atezolizumab. Immune-related adverse events of any grade were observed in 6 patients. In total, 83% proceeded to surgery. Reasons for not undergoing surgery were progression (n = 4), patient choice (n = 2), and death (n = 1). The pathologic complete response rate was 25% (10/40). No statistically significant difference in response or survival was found between the PERFECT and the nCRT cohort. Baseline expression of an established IFNγ signature was higher in responders compared with nonresponders (P = 0.043). On-treatment nonresponders showed either a high number of cytotoxic lymphocytes (CTL) with a transcriptional signature consistent with expression of immune checkpoints, or a low number of CTLs. Conclusions: Combining nCRT with atezolizumab is feasible in patients with rEAC. On the basis of our exploratory biomarker study, future studies are necessary to elucidate the potential of neoadjuvant immunotherapy in patient subgroups. See related commentary by Catenacci, p. 3269

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-4443

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 275

Metadata

Authors
van den Ende, T., de Clercq, N. C., van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Haj Mohammad, N., Ruurda, J. P., van Hillegersberg, R., Mook, S., Nieuwdorp, M., de Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., van Grieken, N. C. T., Bijlsma, M. F., Hulshof, M. C. C. M., & van Laarhoven, H. W. M.
Venue
Clinical Cancer Research
Published
2021-01-27
Volume
27
Issue
12
Pages
3351-3359
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3123367719
Cited by
275
References
29
FWCI
44.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-4443
The paper
van den Ende, T., de Clercq, N. C., van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Haj Mohammad, N., Ruurda, J. P., van Hillegersberg, R., Mook, S., Nieuwdorp, M., de Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., van Grieken, N. C. T., . . . van Laarhoven, H. W. M. (2021). Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-4443

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.